IL3 and cancer: These effects may be attributed to the activation by cholesterol of the estrogen-related α-receptor (ERRα) pathway in macrophages and the release of cytokines by cancer cells, such as eotaxin-1, interleukin-1β (IL-1β), interleukin-3 (IL-3) and IL-6 (50).